Paradigm Biocapital Advisors LP — INSMED INCORPORATED INSM: Quarterly 13F Position History
Paradigm Biocapital Advisors LP has reported INSMED INCORPORATED (INSM) on 18 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2021. As of Q1 2026, the position is sized at 1,254,488 shares ($205.1M market value, 4.19% of the equity book). Quarter-over-quarter share count change: + 1,254,488 (0.0%) .
- 1,254,488Shares Held (Latest Filing)
- $205.1MReported Market Value (Latest Filing)
- 4.19%Portfolio Weight (% of 13F Equity Book)
- +1,254,488Quarter-over-Quarter Share Change
- +$205.1MQuarter-over-Quarter Value Change
- 1,254,488Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 18 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,254,488 | +1,254,488 | — | $205.1M | 4.19% | $163.52 |
| Q4 2025 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2025 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2025 | 0 | 451,359 | -100.0% | $0 | 0.00% | — |
| Q1 2025 | 451,359 | +451,359 | — | $34.4M | 1.59% | $76.29 |
| Q4 2024 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2024 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2024 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2023 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2023 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2022 | 0 | 394,358 | -100.0% | $0 | 0.00% | — |
| Q4 2021 | 394,358 | — | — | $10.7M | 3.07% | $27.24 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a INSM position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported INSMED INCORPORATED (INSM) on its 13F-HR filing for the period ending 2021-12-31 (Q4 2021). The position has appeared on 18 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in INSM?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP added 1,254,488 shares of INSM (0.0%), bringing the total reported position to 1,254,488 shares at a market value of $205.1M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in INSM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.